- Conditions
- Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder, REM Sleep Measurement, Insomnia, Insomnia Related to Specified Disorder, Insomnia Due to Other Mental Disorder, Insomnia Comorbid to Psychiatric Disorder, Insomnia Due to Anxiety and Fear, Insomnia Related to Another Mental Condition, Insomnia Disorders, Idiopathic Hypersomnia, Sleep Disorders, Circadian Rhythm, Post Trauma Nightmares, PTSD - Post Traumatic Stress Disorder, Sleep Quality, Anesthesia, Anxiety, Depression, Mental Health, Alzheimer Disease or Associated Disorder, Parkinsons, Circadian Rhythm, Circadian Dysregulation, PTSD, Post-Traumatic, Post-Traumatic Stress Disorder Complex, Military Combat Stress Reaction, Sleep, Military Activity, Veterans, Shift Work Sleep Disorder, Menopause Related Conditions, Pain, Cancer Pain, Athletes
- Interventions
- PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca, Continuous EEG Monitoring
- Procedure · Drug · Device
- Lead sponsor
- Nyree Penn
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Aventura, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- KarXT, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 70
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 43 more
- Conditions
- Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
- Interventions
- risperidone, quetiapine, olanzapine, divalproex
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimer Disease
- Interventions
- aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 6
- States / cities
- Rosemead, California • Miami, Florida • Nashville, Tennessee + 3 more
- Conditions
- Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
- Interventions
- bifeprunox, Placebo
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Carson, California • Long Beach, California + 28 more
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Interventions
- Brexpiprazole, OPC-34712
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 28
- States / cities
- Imperial, California • Lakewood, California • Long Beach, California + 21 more
- Conditions
- Dementia-related Psychosis
- Interventions
- Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 27
- States / cities
- Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ITI-1284, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 27
- States / cities
- Anaheim, California • Costa Mesa, California • Lafayette, California + 19 more
- Conditions
- Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
- Interventions
- [18F]-PI2620 PET scan
- Diagnostic Test
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Alzheimer Disease
- Interventions
- aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 41
- States / cities
- Tuscaloosa, Alabama • Scottsdale, Arizona • Cerritos, California + 38 more
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Interventions
- Brexpiprazole, OPC-34712, Placebo Oral Tablet
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 37
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
- Conditions
- Schizophrenia, Alzheimer Disease
- Interventions
- Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- La Jolla, California • Eatontown, New Jersey • Austin, Texas
- Conditions
- Alzheimer Disease, Psychosis
- Interventions
- KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • Chino, California • Naples, Florida + 2 more
- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- ACP-204
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 19
- States / cities
- Costa Mesa, California • Fresno, California • Hialeah, Florida + 6 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- KarXT
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 147
- States / cities
- Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ML-007C-MA, Placebo
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 20 more
- Conditions
- Alzheimer's Disease
- Interventions
- Olanzapine, Quetiapine, Risperidone, Citalopram
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 34
- States / cities
- Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more
- Conditions
- Psychosis, Dementia, Aggression, Agitation, Alzheimer Dementia
- Interventions
- MP-101, Placebo
- Drug
- Lead sponsor
- Mediti Pharma Inc.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Pasadena, California • Fairfield, Connecticut + 14 more
- Conditions
- Alzheimer Disease
- Interventions
- KarXT, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 98
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 67 more
- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- ACP-204, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 1,074 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 45
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 29 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ML-007C-MA
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 55 Years to 91 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Doral, Florida • Miami, Florida
- Conditions
- Alzheimer Disease, Healthy Subjects
- Interventions
- NSA-789, placebo
- Drug · Other
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- KarXT, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 58
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more
- Conditions
- Alzheimer's Disease
- Interventions
- Elpipodect, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Santa Ana, California • Cutler Bay, Florida • Hallandale, Florida + 5 more